Sanofi is parting ways with the natural killer cell company Kiadis, three and a half years after buying it for $357 million.
The move was quietly announced via an April 8 update to a clinical trial for SAR445419, an off-the-shelf natural killer cell therapy in development for relapsed/refractory acute myeloid leukemia. The Phase 1 study was apparently terminated due to a “divestment of Kiadis,” per the update to the US clinical trials database.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.